Frequency Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Korro Bio

10/03/2023 12:30

* Frequency Therapeutics Inc  FREQ.OQ   FREQ.O  is expected
to show no change in quarterly revenue when it reports 
results on March 13 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Frequency
Therapeutics
Inc is for a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Frequency
Therapeutics Inc is $4​, above​ its last closing price of $0.62.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.56       -0.57      -0.55     Beat    3.4
 Jun. 30 2022  -0.70       -0.67      -0.61     Beat    9.4
 Mar. 31 2022  -0.62       -0.63      -0.67     Missed  -5.5​
 Dec. 31 2021  0.59        0.15       -0.62     Missed  -506.8
 ​​Sep.        -0.52       -0.57      -0.73     Missed  -27.2
 30 2021                                                
 Jun. 30 2021  -0.51       -0.51      -0.52     Missed  -2.3​
 Mar. 31 2021  -0.28       -0.28      -0.60     Missed  -116.9
 Dec. 31 2020  -0.26       -0.25      -0.30     Missed  -17.8
 This summary was machine generated March 10 at 12:30 GMT.  All
figures in US dollars  unless otherwise stated